Please login to the form below

Not currently logged in
Email:
Password:

Smart Thinking blog

Insights and expert advice on the key issues facing today’s pharma marketer

Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network

The network, called EmerGENE, combines experts from Ashfield Health, Ashfield Engage and Ashfield Advisory

UDG Healthcare company Ashfield has launched a new network offering an end-to-end approach for the commercialisation of cell and gene therapies. 

The network, called EmerGENE, will enable Ashfield to support small and midsize biotech companies with the commercialisation of their discoveries, the agency said in a statement.

EmerGENE was created by a multidisciplinary team and combines experts from Ashfield Health, Ashfield Engage and Ashfield Advisory.

It aims to deliver expert-led guidance and services to biotech companies throughout their clinical to commercial journey.

The network will provide guidance on commercialisation strategic support, early clinical development, distribution and logistics, market access and patient and HCP engagement and support.

“At Ashfield, we look to embed ourselves into our customers’ businesses and use our expertise to create tangible solutions which best meet their needs,” said Amar Urhekar, global president at Ashfield Health.

“EmerGENE is no different, and with over 1,200 cell and gene therapy clinical trials currently underway globally, and 1,000 different manufacturers exploring cell and gene therapies right now, it’s clear that there is demand for support in this space,” he added.

Article by
Lucy Parsons

15th July 2021

From: Communique

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....